Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
Preparing Pre-Investigational New Drug Application for lead drug program SPC-15
Company plans to pursue FDA streamlined 505(b)(2) pathway for clinical drug development
Related news for (SILO)
- Small Caps Aim Big as Digital Asset Strategies Spark Momentum
- MoBot’s Stock Market Highlights – 09/23/25 08:00 AM
- Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security
- 24/7 Market News Snapshot 23 September, 2025 – Silo Pharma, Inc. Common Stock (NASDAQ:SILO)
- Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy
